医学
放射治疗
中枢神经系统
原发性中枢神经系统淋巴瘤
核医学
小学(天文学)
医学物理学
放射科
内科学
物理
天文
作者
Tuğçe Kütük,Ranjini Tolakanahalli,Nicole C. McAllister,Matthew David Hall,Martin C. Tom,Muni Rubens,Haley R. Appel,Alonso N. Gutiérrez,Yazmín Odia,Alexander C. Mohler,Manmeet Singh Ahluwalia,Minesh P. Mehta,Rupesh R Kotecha
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2022-06-15
卷期号:14 (12): 2946-2946
被引量:10
标识
DOI:10.3390/cancers14122946
摘要
Purpose: The objective was to describe PRDR outcomes and report EQD2 OAR toxicity thresholds. Methods: Eighteen patients with recurrent primary CNS tumors treated with PRDR at a single institution between April 2017 and September 2021 were evaluated. The radiotherapy details, cumulative OAR doses, progression-free survival (PFS), overall survival (OS), and toxicities were collected. Results: The median PRDR dose was 45 Gy (range: 36–59.4 Gy); the median cumulative EQD2 prescription dose was 102.7 Gy (range: 93.8–120.4 Gy). The median cumulative EQD2 D0.03cc for the brain was 111.4 Gy (range: 82.4–175.2 Gy). Symptomatic radiation necrosis occurred in three patients, for which the median EQD2 brain D0.03cc was 115.9 Gy (110.4–156.7 Gy). The median PFS and OS after PRDR were 6.3 months (95%CI: 0.9–11.6 months) and 8.6 months (95%CI: 4.9–12.3 months), respectively. The systematic review identified five peer-reviewed studies with a median cumulative EQD2 prescription dose of 110.3 Gy. At a median follow-up of 8.7 months, the median PFS and OS were 5.7 months (95%CI: 2.1–15.4 months) and 6.7 months (95%CI: 3.2–14.2 months), respectively. Conclusion: PRDR re-irradiation is a relatively safe and feasible treatment for recurrent primary CNS tumors. Despite high cumulative dose to OARs, the risk of high-grade, treatment-related toxicity within the first year of follow-up remains acceptable.
科研通智能强力驱动
Strongly Powered by AbleSci AI